SYK
SKI-O-703
- Selective SYK inhibitor for autoimmune disorders
- Proposed indications of SKI-O-703 include rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA) and IgA nephropathy (IgAN), as well as indications such as atopic dermatitis, asthma, allergies, and psoriasis.
- Selective SYK inhibitor for autoimmune disorders
- Proposed indications of SKI-O-703 include rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA) and IgA nephropathy (IgAN), as well as indications such as atopic dermatitis, asthma, allergies, and psoriasis.
FLT3
SKI-G-801
- Intravenous selective FLT3 inhibitor for acute myeloid leukemia
- SKI-G-801 is a highly potent and selective inhibitor against all clinically-known mutations in FLT3. Its superiority compared to any known FLT3 inhibitors
- Intravenous selective FLT3 inhibitor for acute myeloid leukemia
- SKI-G-801 is a highly potent and selective inhibitor against all clinically-known mutations in FLT3. Its superiority compared to any known FLT3 inhibitors
EGFR
GNS-1480 (YH25448)
– Oral 3rd-generation EGFR inhibitor for non-small cell lung cancer (NSCLC)
– Targeting various single and double mutants of EGFR including T790M/L858R and T790M/Del19
– Oral 3rd-generation EGFR inhibitor for non-small cell lung cancer (NSCLC)
– Targeting various single and double mutants of EGFR including T790M/L858R and T790M/Del19
4th–generation EGFR inhibitor program
– Targeting additional mutation of EGFR at amino acid position 797 (C797S), which is a main reason for drug resistance for 3rd generation EGFR inhibitors including Osmertinib®
Publications
Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung Cancer
This article was published on Cancer Research – AACR Journals, doi: 10.1158/0008-5472.CAN-16-2432 in February 2017.
YH25448, a highly selective 3rd generation EGFR TKI, exhibits superior survival benefit over osimertinib in mice with brain metastases of NSCLC
Genosco’s pipeline GNS-1480 (Yuhan code: YH25448) was presented at the IASLC 17th World Conference on Lung Cancer in December 2016.
*IASLC stands for International Association for the Study of Lung Cancer.
Current Partners
